This trial is active, not recruiting.

Condition neurogenic bladder
Treatments tamsolusin, prazosin
Phase phase 1/phase 2
Sponsor Tabriz University
Start date July 2005
End date March 2007
Trial size 80 participants
Trial identifier NCT00602186, 85-1


The purpose of this study is to determine whether Tamsolusin or Prazosin are effective in the treatment of female voiding dysfunction(BOO)

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, outcomes assessor)
Primary purpose treatment
taking Tamsulosin
tamsolusin Flomax
0.4 mg /day
(Active Comparator)
taking prasosin
1 mg/day

Primary Outcomes

patient symptoms improvement(Standard questionare)
time frame: every month untile 3 months

Secondary Outcomes

Urodynamics parameters improvement
time frame: three months later

Eligibility Criteria

Female participants from 20 years up to 70 years old.

Inclusion Criteria: - Healthy females with voiding difficulty with MFR<12 and post void residual urine>50cc Exclusion Criteria: - History of pelvic floor surgury during last 3 month - Any contraindication for Tamsolusin or prazosin

Additional Information

Official title Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction
Description Voiding dysfunction is not uncommon in Tabriz.About 20% of patients in female urology clinic of Tabriz university of medical sciences sufered from some degrees of voiding dysfunction (due to bladder imparement or bladder outlet obstruction).There is limited information about medical treatment of those patients. On the other hand alpha adrenergic blockers are the first choice medication in BENIGN PROSTATIC HYPERPLASIA. There is some new facts about destribution of alpha adrenergic blockers in female pelvic floor.The purpose of this study is to comparision whether Tamsolusin 0.4/daily or Prazosin 1 mg/daily are effective in the treatment of female voiding dysfunction(BOO)
Trial information was received from ClinicalTrials.gov and was last updated in January 2008.
Information provided to ClinicalTrials.gov by Tabriz University.